AVEO Pharmaceuticals, which discovers, develops and commercializes novel cancer therapeutics, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2001 and booked $19 million in sales over the last 12 months, plans to list on the NASDAQ under the symbol AVEO. J.P. Morgan and Morgan Stanley are the lead underwriters on the deal, for which pricing terms were not disclosed.
